Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Single Arm Study to Evaluate the Efficacy, Safety and Local Tolerability of a Subcutaneous 3-month Formulation of Triptorelin Pamoate (11.25 mg) in Patients With Locally Advanced or Metastatic Prostate Cancer

NCT01715129 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT01715129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01715129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Single Arm Study to Evaluate the Efficacy, Safety and Local Tolerability of a Subcutaneous 3-month Formulation of Triptorelin Pamoate (11.25 mg) in Patients With Locally Advanced or Metastatic Prostate Cancer
Lead sponsor
Ipsen
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2013
Completion date
October 31, 2013
Enrollment
126 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer